Business
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification$9.8 million in cash and cash equivalents as of December 31, 2024, in conjunction with LaunXP upfront payment, pipeline focus and expense redu
About this update from Apollomics Inc.
[{"type":"image","alt":"Apollomics Inc.","displaySize":"","headline":null,"caption":"Apollomics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/d34ae079834279a4ee0b836cc8903c4a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/idi4LuS.Th94zbJ6wYl7kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d34ae079834279a4ee0b836cc8903c4a","width":300,"height":116}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination therapy","length":200,"tagName":"p"}]},{"val":[{"type":"text","content":"New interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"$9.8 million in cash and cash equivalents as of December 31, 2024, in conjunction with LaunXP upfront payment, pipeline focus and expense reductions expected to provide cash runway into the first quarter of 2026","length":211,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":569,"olType":false},{"type":"text","content":"FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended December 31, 2024, and highlighted clinical updates and business progress.","length":393,"tagName":"p"},{"type":"text","content":"“Our new partnership with LaunXP provides an opportunity to expand the clinical dataset for vebreltinib to include combination therapy with an EGFRi. This class is currently the frontline treatment for many patients with NSCLC, and combination therapy with vebreltinib may delay the emergence of resistance to this foundational therapeutic class,” said Dr. Guo-Liang Yu, CEO of Apollomics. “We will continue to seek collaborative opportunities to maximize the global opportunity for vebreltinib, both as a single agent and in combination appro...